bpfk.gov.my Report : Visit Site

Technical data of the bpfk.gov.my

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host bpfk.gov.my. Currently, hosted in Malaysia and its service provider is EXA Bytes Network SDN.bhd. .

the related websites

rachempharma.com urlm.co.uk moh.gov.my mopi.org.my drazlantriple-t.com livecharts.co.uk fh.moh.gov.my 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache/2.2.31 (Unix) mod_ssl/2.2.31 OpenSSL/1.0.1e-fips mod_bwlimited/1.4 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

you are using an outdated browser. please upgrade your browser or activate google chrome frame to improve your experience. follow us : language : laman utama profil informasi npra visi, misi & objektif peranan & fungsi carta organisasi piagam pelanggan informatsi kewajipan pencapaian tahunan semasa kakitangan npra borang kemaskini laman web online npra log in rss feed seranta awam pengiktirafan & keahlian antarabangsa pusat kolaborasi who pic/s oecd-glp-mad asean committee anugerah & pengiktirafan pihak berkuasa kawalan dadah pbkd (dca) ahli dca informasi berita dca pengumuman dca malaysian adverse drug reactions advisory committee (madrac) pengenalan madrac members research & project collaboration informasi circular / directive publication npra annual reports newsletter: berita ubat-ubatan newsletter: madrac bulletin national centre for adverse drug reaction monitoring annual report reaksi drug safety news cancellation of complementary & alternative/cosmetic product registered complementary & alternative product notified cosmetic products training & seminars adulterated products (unregistered) new products/indication new products approved (quest2) new products approved (quest3) new products approved (quest3+) new chemical entities additional indications approved quest list of manufacturers / wholesales / importers manufacturers wholesalers importers cosmetic manufacturer list senarai pengilang veterinar yang telah diperiksa dan memenuhi keperluan apb minima garis panduan hubungi kami phone directory location map enquiry / complaint website feedback form faq active pharmaceutical ingredient (api) adr reporting by healthcare professionals clinical trials – safety reporting cosmetic for export only products (feo) gdp glp gmp laboratory & quality control licensing pharmacovigilance - product registration holders product registration quest3+ system reporting by consumers veterinary quest3+ quest3+ log in user manual internet browser products search quest3+ update enquiry / complaint faq 1 2 3 4 5 pengumuman penipuan kutipan derma... published on 13/07/2018 direktif mengenai penerimaan pengesahan pematuhan amalan perkilangan baik (apb) ... published on 16/05/2018 peringatan: tarikh perlaksanaan kawalan regulatori api untuk permohonan baru pro... published on 30/04/2018 lihat semua... sidang media kenyataan akhbar produk-produk kosmetik yang dikesan mengandungi racun berjadual... published on 08/06/2018 kenyataan akhbar produk-produk kosmetik yang dikesan mengandungi racun berjadual... published on 26/02/2018 kenyataan akhbar produk-produk kosmetik yang dikesan mengandungi racun berjadual... published on 30/01/2018 lihat semua... kalendar aktiviti 23 jul module 5 – compliance with gmp for the pharmaceutical engineer (23 – 25 july 2018) – 3 day course 27 ogo module 6 good distribution practices (gdp) for the regulated industry (27 – 29 august 2018) – 3 day course 24 sep module 7 – good aseptic practices & sterile products (24 – 26 september 2018) – 3 day course 22 okt module 8 – solid dosage manufacture principles and practices (22 – 24 october 2018) – 3 day course lihat lagi... pekeliling makluman berkenaan status kemaskini bahan-bahan dalam annexes pada guidelines for control ... published on 07/02/2018 larangan penggunaan nama dan/atau pembungkusan yang sama atau menyerupai dengan produk kos... published on 04/01/2018 lanjutan tarikh pelaksanaan pemakaian guideline for registration of drug-medical device an... published on 03/01/2018 lihat semua... direktif direktif untuk penggunaan drug registration guidance document (drgd) second edition, septe... published on 19/07/2018 direktif untuk semua produk yang mengandungi doxycycline: pengemaskinian sisip bungkusan d... published on 27/06/2018 direktif permohonan pendaftaran semula produk yang pernah didaftarkan secara “pendaftaran ... published on 27/06/2018 lihat semua... npra facebook page national pharmaceutical regulatory agency - npra penerbitan amaran keselamatan borang permohonan industri profesional orang awam statislitik online sebut harga 1 2 3 4 calling for reports: overdose cases with modified-release paracetamol berita ubat-ubatan : march 2018, volume 71 berita ubat-ubatan : december 2017, volume 70 berita ubat-ubatan : september 2017, volume 69 new publication: madrac bulletin - issue 3/2017 berita ubat-ubatan : jun 2017 berita ubat-ubatan : mac 2017 reaksi drug safety news 2017 - issue 6/2017 reaksi drug safety news 2017 - issue 5/2017 new publication: madrac bulletin - issue 2/2017 new publication: madrac bulletin - issue 1/2017 new publication: reaksi drug safety news - issue 4/2017 new publication: reaksi drug safety news - issue 3/2017 new publication: reaksi drug safety news - march 2017 drug registration guidance document (drgd) second edition – september 2016, revi… new publication: bulletin madrac - december 2016 more from this category carbocisteine and acetylcysteine: anaphylactic/anaphylactoid reactions and severe cutaneous adverse reactions (scars) efavirenz: risk of qtcinterval prolongation acetazolamide: risk of severe cutaneous adverse reactions (scars) drug interaction of oral contraceptives containing ethinylestradiol with the direct-acting antiviral combinations of paritaprevir, ritonavir and ombitasvir with or without dasabuvir mesalazine: risk of photosensitivity reactions methotrexate: pulmonary alveolar haemorrhage pemetrexed: risk of nephrogenic diabetes insipidus and renal tubular necrosis amoxicillin-containing products: risk of drug reaction with eosinophilia and systemic symptoms (dress) and strengthening the risk of severe cutaneous adverse reactions (scars) propofol and sodium valproate: risk of increased propofol blood level when co-administered with valproate calling for reports: overdose cases with modified-release paracetamol esmya® 5mg tablets (ulipristal acetate): women taking esmya® for uterine fibroids to have regular liver tests while safety review is ongoing; do not initiate treatment in new patients or those who have completed a previous treatment course doxycycline: risk of jarisch-herxheimer reaction gadolinium-based contrast agents: suspension / restriction of use following evidence of gadolinium deposits in the brain after magnetic resonance imaging (mri) body scans intravenous (iv) fluids containing electrolytes and/or carbohydrates: risk of hyponatraemia levetiracetam and methotrexate: risk of drug-drug interaction ofev® (nintedanib): information on severe liver injury and the need for regular monitoring of liver function associated with the use in patients with idiopathic pulmonary fibrosis (ipf) xofigo® (radium-223 dichloride): important safety information update regarding increased incidence of deaths and fractures in a randomized clinical trial with xofigo® used in combination with abiraterone acetate and prednisolone/ prednisone ribomustin® (bendamustine): increased mortality observed when used in non-approved combination treatments or outside the approved indications; monitor for opportunistic infections and hepatitis b reactivation xgeva® (denosumab): risk of multiple vertebral fractures (mvf) following treatment discontinuation keytruda® (pembrolizumab): risk of stevens-johnson syndrome (sjs) and toxic epidermal necrolysis (ten) zelboraf® (vemurafenib): important drug warning – risk of dupuytren’s contracture and plantar fascial fibromatosis domide® (thalidomide): new important advice regarding viral reactivation and pulmonary hypertension revlimid® (lenalidomide): new important advice regarding viral reactivation madonna® (levonorgestrel): levonorgestrel-containing emergency hormonal contraception ─ new advice on interactions with hepatic enzyme inducers and contraceptive efficacy escapelle® & postinor-2® (levonorgestrel): levonorgestrel-containing emergency hormonal contraception ─ new advice for users of hepatic-enzyme inducers pomalyst® (pomalidomide): new important advice- hepatitis b virus

URL analysis for bpfk.gov.my

http://npra.moh.gov.my/index.php/circular-archives/1263-makluman-berkenaan-status-kemaskini-bahan-bahan-dalam-annexes-pada-guidelines-for-control-of-cosmetic-products-in-malaysia-7-februari-2018
http://npra.moh.gov.my/images/application_form/clinical_trial_forms/2016/300-546-v1_borang_permohonan_ec_19.9.16.doc
http://npra.moh.gov.my/index.php/announcement/1288-national-regulatory-conference-nrc-2018
http://npra.moh.gov.my/index.php/disclaimer
http://npra.moh.gov.my/images/application_form/clinical_trial_forms/2017/pkpb300301borangpermohonanctilversion03tsc11082017clean.docx
http://npra.moh.gov.my/index.php/archives/press-release/1304-press-release-jun-2018
http://npra.moh.gov.my/index.php/announcement/1296-peringatan-tarikh-perlaksanaan-kawalan-regulatori-api-untuk-permohonan-baru-produk-generik-yang-mengandungi-racun-berjadual-bagi-produk-dalam-semua-bentuk-dos-berkuatkuasa-1-julai-2018a
http://npra.moh.gov.my/index.php/faq/adr-reporting-by-healthcare-professionals
http://npra.moh.gov.my/images/application_form/clinical_trial_forms/2016/1611/300-551-v4_borang_permohonan_penilaian_laporan_pemeriksaan_pusat_kajian_be_untuk_pendaftaran_19.10.2016.pdf
http://npra.moh.gov.my/index.php/about-npcb/malaysian-adverse-drug-reactions-advisory-committee-madrac/introduction
http://npra.moh.gov.my/index.php/recent-updates/new-products-indication/quest3plusdcamenu
http://npra.moh.gov.my/index.php/79-safety-alert-2018/1301-calling-for-reports-overdose-cases-with-modified-release-paracetamol
http://npra.moh.gov.my/index.php/about-npcb/npcb-info/npcb-info-2
http://npra.moh.gov.my/index.php/component/content/article?id=1097
http://npra.moh.gov.my/images/application_form/clinical_trial_forms/2016/300-546-v1_borang_permohonan_ec_19.9.16.pdf

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

SERVERS

  SERVER my.whois-servers.net

  ARGS bpfk.gov.my

  PORT 43

DOMAIN

NSERVER

  DNS1.GITN.NET.MY 203.62.1.240

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .